登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《CELL，4月8日，What is required to prevent a second major outbreak of SARS-CoV-2 upon lifting the quarantine of Wuhan city, China》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-04-09

  • What is required to prevent a second major outbreak of SARS-CoV-2 upon lifting the

    quarantine of Wuhan city, China

    Lei Zhang1,2,3,4

    , Mingwang Shen1

    , Xiaomeng Ma5

    , Shu Su1

    , Wenfeng Gong8

    The outbreak of the novel coronavirus SARS-CoV-2 was first identified in the Chinese city of Wuhan in early December 2019, when a group of 27 patients with close contact with a seafood market were diagnosed with a pneumonia of unknown aetiology 1,2

    . The virus was found to be highly contagious and transmit in populations via droplet, person-to-person contact and aerosol transmission 3,4. The number of infected cases increased rapidly in Wuhan during the first few weeks of the outbreak, and then quickly spread to all 31 Chinese provinces and aboard 5,6. As of 20th March 2020, 180 countries worldwide have reported cases of COVID-19. So far, China has reported 80,695 confirmed cases and 3,097 deaths, accounting for about one-third of all cases and deaths worldwide.

  • 原文来源：https://marlin-prod.literatumonline.com/pb-assets/journals/society/the-innovation/PDFs/WhatIsRequiredLiftingQuarantine.pdf
82浏览量
原文链接
相关报告

  • 《MedRxiv，3月30日，What is required to prevent a second major outbreak of the novel coronavirus SARS-CoV-2 upon lifting the metropolitan-wide quarantine of Wuhan city, China》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-31
    • What is required to prevent a second major outbreak of the novel coronavirus SARS-CoV-2 upon lifting the metropolitan-wide quarantine of Wuhan city, China Lei Zhang, Mingwang Shen, Xiaomeng Ma, Shu Su, Wenfeng Gong, Jing Wang, Yusha Tao, Zhuoru Zou, Rui Zhao, Joseph Lau, Wei Li, Feng Liu, Kai Ye, Youfa Wang, Guihua Zhuang, Christopher K Fairley doi: https://doi.org/10.1101/2020.03.24.20042374 Abstract Background: The Chinese government implemented a metropolitan-wide quarantine of Wuhan city on 23rd January 2020 to curb the epidemic of the coronavirus COVID-19. Lifting of this quarantine is imminent. We modelled the effects of two key health interventions on the epidemic when the quarantine is lifted. Method: We constructed a compartmental dynamic model to forecast the trend of the COVID-19 epidemic at different quarantine lifting dates and investigated the impact of different rates of public contact and facial mask usage on the epidemic. Results: We estimated that at the end of the epidemic, a total of 65,572 (46,156-95,264) individuals would be infected by the virus, among which 16,144 (14,422-23,447, 24.6%) would be infected through public contacts, 45,795 (32,390-66,395, 69.7%) through household contact, 3,633 (2,344-5,865, 5.5%) through hospital contacts (including 783 (553-1,134) non-COVID-19 patients and 2,850 (1,801-4,981) medical staff members). *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    85浏览量
    原文链接

  • 《Clinical Chemistry，4月26日，The SARS-CoV-2 Outbreak: Diagnosis, Infection Prevention, and Public Perception》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-27
    • The SARS-CoV-2 Outbreak: Diagnosis, Infection Prevention, and Public Perception Ping Wang, Neil Anderson, Yang Pan, Leo Poon, Carmen Charlton, Nathan Zelyas, David Persing, Daniel Rhoads, Hilary Babcock Clinical Chemistry, hvaa080, https://doi.org/10.1093/clinchem/hvaa080 Published: 26 April 2020 At the end of 2019 and early 2020, an outbreak of pneumonia of unknown etiology emerged in the city of Wuhan in China. The cases were found to be caused by a novel beta coronavirus, which was subsequently named SARS-CoV-2 by the World Health Organization (WHO). The virus has since spread further in China and to other regions of the world, having infected more than 88 K people, and causing close to 3000 deaths as of March 1, 2020. More than 50 million people remain in quarantine at this time. Scientists and clinicians globally are working swiftly to combat COVID-19, the respiratory disease caused by the virus. Notably, diagnostic assays have been developed rapidly in many countries, and have played significant roles in diagnosis, monitoring, surveillance, and infection control. Starting February 29, 2020, the development and performance of molecular testing for SARS-CoV-2 in high complexity Clinical Laboratory Improvement Amendments (CLIA) laboratories prior to emergency use authorization was allowed by the US FDA. Although the epidemic is evolving rapidly, many valuable lessons have been learned and many questions remain to be answered. Here we invited multiple experts across the globe from clinical laboratories, public health laboratories, infection control, and diagnostic industry to share their views on the diagnosis, infection control, and public perception of SARS-CoV-2.
    139浏览量
    原文链接